Psoriasis

InnoCare’s TYK2 Performs Well in Phase II PsO Study
October 9, 2024


Deucravacitinib (Sotyktu) Meets Main Goals in Phase 3b/4 Scalp PsO Study
September 27, 2024

Stress May Kickstart Psoriasis Flare-ups
September 27, 2024



One in Four Psoriasis Patients Show Signs of Psoriatic Arthritis
September 16, 2024

FDA Approves Alembic’s Generic Scalp Psoriasis Treatment
August 28, 2024

Biosimilar Update: EC Approves Stelara Biosimilar
August 26, 2024

Study: Obese Kids May Be More Likely to Develop AD, PsO, or AA
August 21, 2024

Otezla Now Available for Kids With Moderate to Severe Psoriasis
August 20, 2024

Just Published: NPF’s Psoriasis Health Indicator Report
August 16, 2024